Stargardt disease gene therapy - HuidaGene Therapeutics
Alternative Names: STGD1-HuidaGene TherapeuticsLatest Information Update: 26 Oct 2023
Price :
$50 *
At a glance
- Originator HuidaGene Therapeutics
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research Stargardt disease
Most Recent Events
- 12 Sep 2023 Stargardt disease therapeutic - HuidaGene Therapeutics is available for licensing as of 12 Sep 2023. https://www.huidagene.com/licensing
- 12 Sep 2023 Early research in Stargardt disease in China (Parenteral) (Huidagene pipeline, September 2023)